



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/27, 47/10		A2	(11) International Publication Number: WO 98/29131 (43) International Publication Date: 9 July 1998 (09.07.98)
<p>(21) International Application Number: PCT/US97/23497</p> <p>(22) International Filing Date: 31 December 1997 (31.12.97)</p> <p>(30) Priority Data: 60/033,971 31 December 1996 (31.12.96) US</p> <p>(71) Applicant: MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).</p> <p>(72) Inventor: HEINZ, Daniel, Nicholas; 1436 Summer Haven Drive, St. Louis, MO 63146 (US).</p> <p>(74) Agent: WAACK, Janelle, D.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: AQUEOUS GLYCEROL FORMULATIONS OF SOMATOTROPIN</p> <p>(57) Abstract</p> <p>Aqueous somatotropin compositions are presented that contain less than about 10 % of a biologically active somatotropin, water, and glycerol in an amount effective and at a pH effective to maintain the somatotropin substantially completely stable. The somatotropins in such compositions preferably retain their physical and chemical stability for at least 2 years. The somatotropin compositions also preferably have anti-microbial activity, such that, after they have been sterile-filtered, no additional anti-microbial agent is necessary to maintain the sterility of the composition.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AQUEOUS GLYCEROL FORMULATIONS OF SOMATOTROPIN

This application claims the benefit of U.S. provisional application Serial No. 60/033,971, filed December 31, 1996.

BACKGROUND OF THE INVENTION

5 Somatotropins (growth hormones) were originally discovered in pituitary extracts of various animals, and may now be produced using recombinant DNA by conventional genetic engineering techniques. Somatotropins may be administered to animals using a variety of formulations and administration techniques. One major problem in the administration of somatotropins is the denaturation of their active globular structure, which
10 may cause somatotropins to oligomerize (e.g., dimerize) and/or aggregate and precipitate, thereby decreasing the amount of available somatotropin in solution as well as the somatotropin bioactivity. Previously, formulations have been developed which incorporate a stabilizer in an attempt to decrease the formation of insolubles and maintain the bioactivity of the somatotropin.

15

For example, European Patent Application specification no. 374,120 (Monsanto Co.) refers to somatotropin compositions containing at least about 10% bioactive somatotropin, an effective amount of a stabilizing polyol, such as glycerol, and a buffer to achieve a pH in the range of 4.5 to either about 7 or the isoelectric point of the somatotropin, whichever is greater. This formulation is preferably administered to an animal from an implantable dispenser for controlled release over an extended period of time. The compositions of that specification preferably contain a bovine or porcine somatotropin.

20 There is a need in the art for novel somatotropin formulations that have good long term chemical and physical stability, preferably such that they qualify for FDA approval of labeling regarding long term shelf life. There is also a need for multi-dose somatotropin formulations that do not require additional anti-microbial agents to retain the stability and bioactivity of the formulation. Additionally, there is a need for somatotropin formulations

SUMMARY OF THE INVENTION

This invention generally relates to aqueous glycerol formulations of a biologically active somatotropin. More particularly, this invention relates to aqueous somatotropin compositions comprising less than about 10% of a biologically active somatotropin, water, and glycerol in an amount effective and at a pH effective to maintain the somatotropin substantially completely stable. In a preferred embodiment, the somatotropins in such compositions retain their physical and chemical stability for at least 2 years. The somatotropin compositions according to the invention also have anti-microbial activity, such that, after they have been sterile-filtered, no additional anti-microbial agent is necessary to maintain the sterility of the composition.

In a preferred embodiment, the inventive somatotropin compositions are suitable for parenteral administration to companion animals, such as dogs and cats, and are preferably suitable for multiple dose packaging.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

For purposes of this invention, the term "somatotropin" includes mammalian somatotropins, such as human, ovine, porcine, bovine, equine, canine and feline somatotropins, particularly canine and feline somatotropins; and others such as avian somatotropin. The term "somatotropins" includes somatotropin proteins and salts thereof having naturally-occurring sequences as well as variants of the naturally-occurring proteins having somatotropin-like bioactivity. For example, "somatotropin" includes somatotropin proteins that have been modified at the N-terminus, *e.g.*, by deleting an N-terminal methionine group or replacing it with another amino acid, or proteins that have other amino acid substitutions, additions or deletions but yet provide somatotropin-like activity, *i.e.*, they bind to somatotropin receptors in the animal with sufficient affinity to result in improvement of growth, lactation, feed efficiency and/or health of the animal.

The somatotropins for use in the present invention can be derived by extraction and subsequent concentration techniques from the pituitary glands of various animals. More preferably, somatotropins produced by recombinant DNA methods are used in the inventive

compositions. The somatotropin to be formulated can be a heavy metal (e.g., zinc) derivative of the somatotropin, or it can be free from association with such a metal. The somatotropin to be formulated can also be a powder (e.g., lyophilized) or in aqueous solution.

5

The proportion of somatotropin in the inventive compositions may vary, for example, depending upon the size and type of animal being treated as well as the desired dosage and treatment strategy. The somatotropin content of the inventive composition is less than about 10% by weight of the composition. The composition preferably has a 10 somatotropin content of less than about 8% by weight of the composition, more preferably less than about 6%. In further preferred embodiments, the composition has a somatotropin content of at least about 0.01%, preferably at least about 0.3% by weight; up to about 5% and commonly up to about 3% by weight.

15

The inventive compositions further contain water and glycerol, preferably in an amount such that the glycerol : water volume ratio is not less than about 1:1 to ensure antimicrobial activity, and not greater than about 4:1, to facilitate an efficient sterile filtration rate.

20

Generally, the pH of the inventive aqueous glycerol somatotropin composition is between about 4.5 and the greater of about 7 and about the isoelectric point of the somatotropin. More preferably, the pH of the composition is in the range of about 6 to about 7.

25

In a preferred embodiment, the inventive formulation further contains one or more additives such as a surfactant, a wetting agent and/or an anti-foaming agent. For example, a non-ionic surfactant may be added in an amount sufficient to lower the surface tension and yet minimize adverse site reactions. For example, the surfactant additive may be a polyethoxylated sorbitan ester, such as a tri(polyoxyethylene) ester of sorbitan mono-oleate (available as Tween 80 from ICI Americas Inc.), which may also act as a wetting agent to promote the wetting of the somatotropin by a buffer and glycerol excipient during

preparation and may further prevent foaming. The surfactant can be present in a concentration ranging from about 0.005% to about 2.5%, and more preferably from about 0.05% to about 1.0% of the composition.

5 The inventive aqueous glycerol formulations of somatotropin are chemically and physically stable and substantially completely retain the bioactivity of the somatotropin. The inventive formulations preferably remain stable for at least 2 years, more preferably at least 3 years and most preferably for at least 4 years. This stability characteristic is determined by observing the formulations for dimer and aggregate formation, as well as for 10 turbidity, at various temperatures over a period of time, which simulates the long term performance of the formulation stability. A formulation is considered substantially completely stable if less than 10% of the somatotropin is found in the form of dimer and aggregates after storage of the formulation at 4°C for 2 years, and visibly remains clear and does not settle out during such storage.

15 The inventive aqueous glycerol formulations have anti-microbial activity, and accordingly, no further anti-microbial agent or preservative need be added to the composition. The anti-microbial activity of the inventive formulations is largely due to the high glycerol content. The inventive aqueous glycerol formulations are also usually 20 subjected to sterile filtration.

In a preferred embodiment, the aqueous glycerol formulations of somatotropin according to the invention are suitable for parenteral administration to companion animals, particularly to dogs and cats. For example, the inventive somatotropin composition may 25 contain canine somatotropin and be administered to dogs for the treatment of alopecia, bone fractures and other injuries and diseases suitably treated using the cell proliferation and other biological activities of a somatotropin. In a further preferred embodiment, the aqueous glycerol formulations are adequate compositions for a commercial multi-dose product. These formulations can be administered in a variety of ways, including parenteral 30 administration, such as subcutaneous, intramuscular or intraperitoneal techniques or via an

implanted delivery device. For companion animals, the preferred method of administration is parenteral administration via subcutaneous injection.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLES

Example 1. Preparation of aqueous glycerol formulation of porcine somatotropin

10.5 g of pST powder was added to 1 L of an excipient (65:35, glycerol : water by volume, 0.15% Tween 80 surfactant by volume, pH 6.3 phosphate buffer and 3% potassium chloride by weight) and the mixture was stirred for ½ hour at ambient temperature. This formulation was then sterile filtered through a 0.22 μm filter.

Example 2. Preparation of excipient

3.747 kg of WFI (water for injection) was added to a vessel and agitated at moderate r.p.m. The vessel was then charged with sodium phosphate monobasic (0.143 kg), sodium phosphate dibasic (0.175 kg) and potassium chloride (0.252 kg). The resulting mixture was stirred until all solids dissolved. This dissolution was endothermic and the mixture cooled to 15-20°C. The vessel was then further charged with 7.665 kg of glycerol and 0.0182 kg of Tween 80. The mixture warmed up to about 30°C. The mixture was then cooled to a temperature of 20-25°C by cooling coils/jacket and agitation.

A 50-55 g sample was then removed and analyzed. The sample was a clear, colorless liquid having a pH at 20-25°C of 6.1-6.6 and a density at 22°C of 1.20 ± 0.02 g/cc.

Example 3. Preparation of bovine somatotropin formulation

The excipient prepared in Example 2 was stirred at a temperature of 20-25°C. ZnbST in the form of bulk powder (0.0521 kg) was then added over a period of 20-30 minutes. After all of the ZnbST powder was added, the mixture was stirred for an additional 50-60 minutes at 20-25°C. During this period, the excipient turned turbid due to the formation of zinc phosphate salts. The mixture was then heated to 36-40°C for 80-100 min. Subsequently, the mixture was cooled to 20-25°C and stirred for at least 30 minutes.

The bST/excipient formulation was then filtered by connecting a Millipore Millipak 10 200, 0.22 µm disposable filter unit to the discharge port of the formulation vessel. The formulation vessel was placed under a regulated air pressure of 15 psig and the discharge port was opened. The filtration was complete in less than 15 minutes with a small decrease in the filtration rate over the cycle time.

15 Example 4. Stability testing of aqueous glycerol formulation of bST

Samples of aqueous glycerol formulations of bovine somatotropin were stored for periods of time up to 120 days at temperatures of 4°C, 22°C and 39°C.

Chemical stability was evaluated based on dimer/aggregate formation. The 20 formulation according to the invention had no detectable dimer or aggregate formation at 4°C or 22°C for up to 75 days, which is very atypical and unusually stable for storage of such formulations, particularly at 22°C. About 2% dimer/aggregate formation occurred at 39°C at the 75th day, which is a surprisingly good result at such a high temperature in having a low dimer/aggregate formation.

25 Physical stability was evaluated based on the turbidity of the samples. The formulation according to the invention had no visually observable turbidity change at 4°C or 22°C for up to 120 days, which is very atypical and unusually stable, particularly at 22°C. Signs of very slight turbidity were observed after 20-22 days at 39°C. This stability is still considered extremely good.

While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the process described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.

10. The following is a list of the compositions and methods of this invention:

11. A composition of matter consisting of a mixture of:

12. A method of preparing a composition of matter consisting of:

13. A composition of matter consisting of:

14. A method of preparing a composition of matter consisting of:

15. A composition of matter consisting of:

16. A method of preparing a composition of matter consisting of:

17. A composition of matter consisting of:

18. A method of preparing a composition of matter consisting of:

19. A composition of matter consisting of:

20. A method of preparing a composition of matter consisting of:

21. A composition of matter consisting of:

22. A method of preparing a composition of matter consisting of:

23. A composition of matter consisting of:

24. A method of preparing a composition of matter consisting of:

25. A composition of matter consisting of:

26. A method of preparing a composition of matter consisting of:

27. A composition of matter consisting of:

28. A method of preparing a composition of matter consisting of:

29. A composition of matter consisting of:

WHAT IS CLAIMED IS:

1. An aqueous glycerol somatotropin composition comprising:
a biologically active somatotropin in a concentration less than about 8% by weight of the composition, water and glycerol in an amount effective and at a pH effective to maintain the somatotropin substantially completely stable.
2. The composition of claim 1, wherein the somatotropin is bovine somatotropin, porcine somatotropin, ovine somatotropin, equine somatotropin, canine somatotropin or feline somatotropin.
3. The composition of claim 2, wherein the somatotropin is canine somatotropin or feline somatotropin.
4. The composition of claim 1, wherein the composition has a pH in the range of about 4.5 to the higher of about 7 and the isoelectric point of the somatotropin.
5. The composition of claim 4, wherein the composition has a pH in the range of about 6 to about 7.
6. The composition of claim 1, wherein the composition further comprises a non-ionic surfactant.
7. The composition of claim 6, wherein the non-ionic surfactant is present in an amount in the range of 0.05 to 1.0% by weight of the composition.
8. The composition of claim 6, wherein the non-ionic surfactant comprises a polyethoxylated sorbitan ester.
9. The composition of claim 8, wherein the non-ionic surfactant is a tri(polyoxyethylene) ester of sorbitan mono-oleate.

9. The composition of claim 8, wherein the non-ionic surfactant is a tri(polyoxyethylene) ester of sorbitan mono-oleate.
10. The composition of claim 1, wherein the composition is substantially completely stable for at least 2 years.
11. The composition of claim 1, wherein the composition has undergone sterile filtration.
12. The composition of claim 1, wherein the composition contains no additional antimicrobial agent.
13. The composition of claim 1, wherein the somatotropin is present in a concentration less than about 6% by weight.
14. The composition of claim 1, wherein the somatotropin is present in a concentration between about 0.01 and about 5% by weight.
15. The composition of claim 1, wherein the somatotropin is present in a concentration between about 0.3 and about 3% by weight.
16. The composition of claim 1, wherein the ratio of glycerol to water by volume is in the range of about 1:1 to about 4:1.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/27, 47/10		A3	(11) International Publication Number: WO 98/29131 (43) International Publication Date: 9 July 1998 (09.07.98)
<p>(21) International Application Number: PCT/US97/23497</p> <p>(22) International Filing Date: 31 December 1997 (31.12.97)</p> <p>(30) Priority Data: 60/033,971 31 December 1996 (31.12.96) US</p> <p>(71) Applicant: MONSANTO COMPANY (US/US); 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).</p> <p>(72) Inventor: HEINZ, Daniel, Nicholas; 1436 Summer Haven Drive, St. Louis, MO 63146 (US).</p> <p>(74) Agent: WAACK, Janelle, D.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 1 October 1998 (01.10.98)</p>	
<p>(54) Title: AQUEOUS GLYCEROL FORMULATIONS OF SOMATOTROPIN</p> <p>(57) Abstract</p> <p>Aqueous somatotropin compositions are presented that contain less than about 10 % of a biologically active somatotropin, water, and glycerol in an amount effective and at a pH effective to maintain the somatotropin substantially completely stable. The somatotropins in such compositions preferably retain their physical and chemical stability for at least 2 years. The somatotropin compositions also preferably have anti-microbial activity, such that, after they have been sterile-filtered, no additional anti-microbial agent is necessary to maintain the sterility of the composition.</p>			

*(Referred to in PCT Gazette No. 44/1998, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	USA	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AQUEOUS GLYCEROL FORMULATIONS OF SOMATOTROPIN

This application claims the benefit of U.S. provisional application Serial No. 60/033,971, filed December 31, 1996.

BACKGROUND OF THE INVENTION

5 Somatotropins (growth hormones) were originally discovered in pituitary extracts of various animals, and may now be produced using recombinant DNA by conventional genetic engineering techniques. Somatotropins may be administered to animals using a variety of formulations and administration techniques. One major problem in the administration of somatotropins is the denaturation of their active globular structure, which 10 may cause somatotropins to oligomerize (e.g., dimerize) and/or aggregate and precipitate, thereby decreasing the amount of available somatotropin in solution as well as the somatotropin bioactivity. Previously, formulations have been developed which incorporate a stabilizer in an attempt to decrease the formation of insolubles and maintain the bioactivity 15 of the somatotropin.

15

For example, European Patent Application specification no. 374,120 (Monsanto Co.) refers to somatotropin compositions containing at least about 10% bioactive somatotropin, an effective amount of a stabilizing polyol, such as glycerol, and a buffer to achieve a pH in the range of 4.5 to either about 7 or the isoelectric point of the somatotropin, whichever is greater. This formulation is preferably administered to an animal from an implantable dispenser for controlled release over an extended period of time. The compositions of that specification preferably contain a bovine or porcine somatotropin.

20 There is a need in the art for novel somatotropin formulations that have good long term chemical and physical stability, preferably such that they qualify for FDA approval of labeling regarding long term shelf life. There is also a need for multi-dose somatotropin formulations that do not require additional anti-microbial agents to retain the stability and bioactivity of the formulation. Additionally, there is a need for somatotropin formulations

SUMMARY OF THE INVENTION

This invention generally relates to aqueous glycerol formulations of a biologically active somatotropin. More particularly, this invention relates to aqueous somatotropin compositions comprising less than about 10% of a biologically active somatotropin, water, and glycerol in an amount effective and at a pH effective to maintain the somatotropin substantially completely stable. In a preferred embodiment, the somatotropins in such compositions retain their physical and chemical stability for at least 2 years. The somatotropin compositions according to the invention also have anti-microbial activity, such that, after they have been sterile-filtered, no additional anti-microbial agent is necessary to maintain the sterility of the composition.

In a preferred embodiment, the inventive somatotropin compositions are suitable for parenteral administration to companion animals, such as dogs and cats, and are preferably suitable for multiple dose packaging.

15

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

For purposes of this invention, the term "somatotropin" includes mammalian somatotropins, such as human, ovine, porcine, bovine, equine, canine and feline somatotropins, particularly canine and feline somatotropins; and others such as avian somatotropin. The term "somatotropins" includes somatotropin proteins and salts thereof having naturally-occurring sequences as well as variants of the naturally-occurring proteins having somatotropin-like bioactivity. For example, "somatotropin" includes somatotropin proteins that have been modified at the N-terminus, *e.g.*, by deleting an N-terminal methionine group or replacing it with another amino acid, or proteins that have other amino acid substitutions, additions or deletions but yet provide somatotropin-like activity, *i.e.*, they bind to somatotropin receptors in the animal with sufficient affinity to result in improvement of growth, lactation, feed efficiency and/or health of the animal.

The somatotropins for use in the present invention can be derived by extraction and subsequent concentration techniques from the pituitary glands of various animals. More preferably, somatotropins produced by recombinant DNA methods are used in the inventive

compositions. The somatotropin to be formulated can be a heavy metal (e.g., zinc) derivative of the somatotropin, or it can be free from association with such a metal. The somatotropin to be formulated can also be a powder (e.g., lyophilized) or in aqueous solution.

5

The proportion of somatotropin in the inventive compositions may vary, for example, depending upon the size and type of animal being treated as well as the desired dosage and treatment strategy. The somatotropin content of the inventive composition is less than about 10% by weight of the composition. The composition preferably has a somatotropin content of less than about 8% by weight of the composition; more preferably less than about 6%. In further preferred embodiments, the composition has a somatotropin content of at least about 0.01%, preferably at least about 0.3% by weight; up to about 5% and commonly up to about 3% by weight.

15

The inventive compositions further contain water and glycerol, preferably in an amount such that the glycerol : water volume ratio is not less than about 1:1 to ensure antimicrobial activity, and not greater than about 4:1, to facilitate an efficient sterile filtration rate.

20

Generally, the pH of the inventive aqueous glycerol somatotropin composition is between about 4.5 and the greater of about 7 and about the isoelectric point of the somatotropin. More preferably, the pH of the composition is in the range of about 6 to about 7.

25

In a preferred embodiment, the inventive formulation further contains one or more additives such as a surfactant, a wetting agent and/or an anti-foaming agent. For example, a non-ionic surfactant may be added in an amount sufficient to lower the surface tension and yet minimize adverse site reactions. For example, the surfactant additive may be a polyethoxylated sorbitan ester, such as a tri(polyoxyethylene) ester of sorbitan mono-oleate

30

(available as Tween 80 from ICI Americas Inc.), which may also act as a wetting agent to promote the wetting of the somatotropin by a buffer and glycerol excipient during

preparation and may further prevent foaming. The surfactant can be present in a concentration ranging from about 0.005% to about 2.5%, and more preferably from about 0.05% to about 1.0% of the composition.

5 The inventive aqueous glycerol formulations of somatotropin are chemically and physically stable and substantially completely retain the bioactivity of the somatotropin. The inventive formulations preferably remain stable for at least 2 years, more preferably at least 3 years and most preferably for at least 4 years. This stability characteristic is determined by observing the formulations for dimer and aggregate formation, as well as for 10 turbidity, at various temperatures over a period of time, which simulates the long term performance of the formulation stability. A formulation is considered substantially completely stable if less than 10% of the somatotropin is found in the form of dimer and aggregates after storage of the formulation at 4°C for 2 years, and visibly remains clear and does not settle out during such storage.

15 The inventive aqueous glycerol formulations have anti-microbial activity, and accordingly, no further anti-microbial agent or preservative need be added to the composition. The anti-microbial activity of the inventive formulations is largely due to the high glycerol content. The inventive aqueous glycerol formulations are also usually 20 subjected to sterile filtration.

In a preferred embodiment, the aqueous glycerol formulations of somatotropin according to the invention are suitable for parenteral administration to companion animals, particularly to dogs and cats. For example, the inventive somatotropin composition may 25 contain canine somatotropin and be administered to dogs for the treatment of alopecia, bone fractures and other injuries and diseases suitably treated using the cell proliferation and other biological activities of a somatotropin. In a further preferred embodiment, the aqueous glycerol formulations are adequate compositions for a commercial multi-dose 30 product. These formulations can be administered in a variety of ways, including parenteral administration, such as subcutaneous, intramuscular or intraperitoneal techniques or via an

implanted delivery device. For companion animals, the preferred method of administration is parenteral administration via subcutaneous injection.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLES

Example 1. Preparation of aqueous glycerol formulation of porcine somatotropin

15 10.5 g of pST powder was added to 1 L of an excipient (65:35, glycerol : water by volume, 0.15% Tween 80 surfactant by volume, pH 6.3 phosphate buffer and 3% potassium chloride by weight) and the mixture was stirred for ½ hour at ambient temperature. This formulation was then sterile filtered through a 0.22 μm filter.

20 Example 2. Preparation of excipient

3.747 kg of WFI (water for injection) was added to a vessel and agitated at moderate r.p.m. The vessel was then charged with sodium phosphate monobasic (0.143 kg), sodium phosphate dibasic (0.175 kg) and potassium chloride (0.252 kg). The resulting mixture was stirred until all solids dissolved. This dissolution was endothermic and the mixture cooled 25 to 15-20°C. The vessel was then further charged with 7.665 kg of glycerol and 0.0182 kg of Tween 80. The mixture warmed up to about 30°C. The mixture was then cooled to a temperature of 20-25°C by cooling coils/jacket and agitation.

30 A 50-55 g sample was then removed and analyzed. The sample was a clear, colorless liquid having a pH at 20-25°C of 6.1-6.6 and a density at 22°C of 1.20 \pm 0.02 g/cc.

Example 3. Preparation of bovine somatotropin formulation

The excipient prepared in Example 2 was stirred at a temperature of 20-25°C. ZnbST in the form of bulk powder (0.0521 kg) was then added over a period of 20-30 minutes. After all of the ZnbST powder was added, the mixture was stirred for an additional 50-60 minutes at 20-25°C. During this period, the excipient turned turbid due to the formation of zinc phosphate salts. The mixture was then heated to 36-40°C for 80-100 min. Subsequently, the mixture was cooled to 20-25°C and stirred for at least 30 minutes.

The bST/excipient formulation was then filtered by connecting a Millipore Millipak-10 200, 0.22 µm disposable filter unit to the discharge port of the formulation vessel. The formulation vessel was placed under a regulated air pressure of 15 psig and the discharge port was opened. The filtration was complete in less than 15 minutes with a small decrease in the filtration rate over the cycle time.

15 Example 4. Stability testing of aqueous glycerol formulation of bST

Samples of aqueous glycerol formulations of bovine somatotropin were stored for periods of time up to 120 days at temperatures of 4°C, 22°C and 39°C.

Chemical stability was evaluated based on dimer/aggregate formation. The 20 formulation according to the invention had no detectable dimer or aggregate formation at 4°C or 22°C for up to 75 days, which is very atypical and unusually stable for storage of such formulations, particularly at 22°C. About 2% dimer/aggregate formation occurred at 39°C at the 75th day, which is a surprisingly good result at such a high temperature in having a low dimer/aggregate formation.

25 Physical stability was evaluated based on the turbidity of the samples. The formulation according to the invention had no visually observable turbidity change at 4°C or 22°C for up to 120 days, which is very atypical and unusually stable, particularly at 22°C. Signs of very slight turbidity were observed after 20-22 days at 39°C. This stability is still considered extremely good.

While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the process described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.

the 1820s, the first major period of industrialization in the United States, the country's population grew rapidly, and the demand for labor increased. This led to a significant increase in the number of immigrants, particularly from Europe, who came to the United States in search of work and a better life. The industrial revolution also led to the development of new technologies and industries, such as the textile industry, which required a large amount of labor. The demand for labor in these industries led to the growth of the labor market, and the need for workers to be paid fairly and justly.

... THE JAPANESE PROBLEMS

WHAT IS CLAIMED IS:

1. An aqueous glycerol somatotropin composition comprising:
a biologically active somatotropin in a concentration less than about 8% by weight of the composition, water and glycerol in an amount effective and at a pH effective to maintain the somatotropin substantially completely stable.
2. The composition of claim 1, wherein the somatotropin is bovine somatotropin, porcine somatotropin, ovine somatotropin, equine somatotropin, canine somatotropin or feline somatotropin.
3. The composition of claim 2, wherein the somatotropin is canine somatotropin or feline somatotropin.
4. The composition of claim 1, wherein the composition has a pH in the range of about 4.5 to the higher of about 7 and the isoelectric point of the somatotropin.
5. The composition of claim 4, wherein the composition has a pH in the range of about 6 to about 7.
6. The composition of claim 1, wherein the composition further comprises a non-ionic surfactant.
7. The composition of claim 6, wherein the non-ionic surfactant is present in an amount in the range of 0.05 to 1.0% by weight of the composition.
8. The composition of claim 6, wherein the non-ionic surfactant comprises a polyethoxylated sorbitan ester.

9. The composition of claim 8, wherein the non-ionic surfactant is a tri(polyoxyethylene) ester of sorbitan mono-oleate.

10. The composition of claim 1, wherein the composition is substantially completely stable for at least 2 years.

11. The composition of claim 1, wherein the composition has undergone sterile filtration.

10 12. The composition of claim 1, wherein the composition contains no additional antimicrobial agent.

13. The composition of claim 1, wherein the somatotropin is present in a concentration less than about 6% by weight.

15 14. The composition of claim 1, wherein the somatotropin is present in a concentration between about 0.01 and about 5% by weight.

15. The composition of claim 1, wherein the somatotropin is present in a concentration 20 between about 0.3 and about 3% by weight.

16. The composition of claim 1, wherein the ratio of glycerol to water by volume is in the range of about 1:1 to about 4:1.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/23497

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/27 A61K47/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 122, no. 26, 26 June 1995 Columbus, Ohio, US; abstract no. 322396, XP002069690 see abstract & ANONYMOUS: "SALT-STABILIZED PROTEIN FORMULATIONS" RESEARCH DISCLOSURES, vol. 370, no. 013, 10 February 1995, UK, pages 56-57,</p> <p style="text-align: center;">-/-</p>	1-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

³ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 1998

Date of mailing of the international search report

04/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarpioni, U

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 97/23497

C.(Continuation)-DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE WPI Week 8927 Derwent Publications Ltd., London, GB; AN 89-192875 '25! XP002069691 see abstract & AU 24621 88 A (LILLY) 11 May 1989	1-16
A	EP 0 213 851 A (LILLY) 11 March 1987 see the whole document	1-16
A	WO 93 19776 A (KABI PHARMACIA) 14 October 1993 see the whole document	1-16
A	EP 0 374 120 A (MONSANTO) 20 June 1990 cited in the application see the whole document	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/23497

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 213851 A	11-03-1987	US 4775659 A AU 596806 B AU 6119986 A CA 1269933 A DE 3684386 A DK 386986 A IE 59130 B JP 1983208 C JP 7010781 B JP 62045538 A	04-10-1988 17-05-1990 26-02-1987 05-06-1990 23-04-1992 20-02-1987 12-01-1994 25-10-1995 08-02-1995 27-02-1987
WO 9319776 A	14-10-1993	AU 3913593 A CA 2102693 A EP 0587858 A JP 6508156 T NO 934355 A NZ 251498 A US 5567677 A	08-11-1993 04-10-1993 23-03-1994 14-09-1994 01-12-1993 26-07-1995 22-10-1996
EP 374120 A	20-06-1990	AU 4617689 A CA 2005226 A CN 1043631 A CZ 8907028 A DK 626089 A JP 2204418 A PT 92548 A	21-06-1990 13-06-1990 11-07-1990 18-01-1995 14-06-1990 14-08-1990 29-06-1990